Junhao Wen,Zhijian Yang,Ilya M. Nasrallah,Yuhan Cui,Guray Erus,Dhivya Srinivasan,Ahmed Abdulkadir,Elizabeth Mamourian,Ioanna Skampardoni,Gyujoon Hwang,Ashish Singh,Mark Bergman,Jingxuan Bao,Erdem Varol,Zhen Zhou,Aleix Boquet-Pujadas,Jiong Chen,Arthur W. Toga,Andrew J. Saykin,Timothy J. Hohman,Paul M. Thompson,Sylvia Villeneuve,Randy Gollub,Aristeidis Sotiras,Katharina Wittfeld,Hans J. Grabe,Duygu Tosun,Murat Bilgel,Yang An,Daniel S. Marcus,Pamela LaMontagne,Tammie L. Benzinger,Susan R. Heckbert,Thomas R. Austin,Lenore J. Launer,Mark Espeland,Colin L Masters,Paul Maruff,Jurgen Fripp,Sterling C. Johnson,John C. Morris,Marilyn S. Albert,R. Nick Bryan,Susan M. Resnick,Luigi Ferrucci,Yong Fan,Mohamad Habes,David Wolk,Li Shen,Haochang Shou,Christos Davatzikos

Abstract:Alzheimer’s disease (AD) is associated with heterogeneous atrophy patterns. We employed a semi-supervised clustering technique known as Surreal-GAN, through which we identified two dominant dimensions of brain atrophy in symptomatic mild cognitive impairment (MCI) and AD patients: the “diffuse-AD” (R1) dimension shows widespread brain atrophy, and the “MTL-AD” (R2) dimension displays focal medial temporal lobe (MTL) atrophy. Critically, only R2 was associated with widely known sporadic AD genetic risk factors (e.g., APOE ε4 ) in MCI and AD patients at baseline. We then independently detected the presence of the two dimensions in the early stages by deploying the trained model in the general population and two cognitively unimpaired cohorts of asymptomatic participants. In the general population, genome-wide association studies found 77 genes unrelated to APOE differentially associated with R1 and R2. Functional analyses revealed that these genes were overrepresented in differentially expressed gene sets in organs beyond the brain (R1 and R2), including the heart (R1) and the pituitary gland, muscle, and kidney (R2). These genes were enriched in biological pathways implicated in dendritic cells (R2), macrophage functions (R1), and cancer (R1 and R2). Several of them were “druggable genes” for cancer (R1), inflammation (R1), cardiovascular diseases (R1), and diseases of the nervous system (R2). The longitudinal progression showed that APOE ε4 , amyloid, and tau were associated with R2 at early asymptomatic stages, but this longitudinal association occurs only at late symptomatic stages in R1. Our findings deepen our understanding of the multifaceted pathogenesis of AD beyond the brain. In early asymptomatic stages, the two dimensions are associated with diverse pathological mechanisms, including cardiovascular diseases, inflammation, and hormonal dysfunction – driven by genes different from APOE – which may collectively contribute to the early pathogenesis of AD.### Competing Interest StatementDAW served as Site PI for studies by Biogen, Merck, and Eli Lilly Avid. He has received consulting fees from GE Healthcare and Neuronix. He is on the DSMB for a trial sponsored by Functional Neuromodulation. AJS receives support from multiple NIH grants, P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177. He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, in kind contribution of PET tracer precursor, Bayer Oncology Scientific Advisory Board, Eisai Scientific Advisory Board, Siemens Medical Solutions USA, Inc. Dementia Advisory Board, Springer-Nature Publishing Editorial Office Support as Editor in Chief, Brain Imaging, and Behavior. ME receives support from multiple NIH grants, the Alzheimers Association, and the Alzheimer Therapeutic Research Institute. HJG has received travel grants and speaker honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen Cilag as well as research funding from Fresenius Medical Care. HJG had personal contracts approved by the university administration for speaker honoraria and one IIT with Fresenius Medical Care. AA was supported by grants 191026 and 206795 from the Swiss National Science Foundation

Hypothesis-based investigation of known AD risk variants reveals the genetic underpinnings of neuropathological lesions observed in Alzheimer's-type dementia

Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk

GWAS of multiple neuropathology endophenotypes identifies new risk loci and provides insights into the genetic risk of dementia

Alzheimer's disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non-demented individuals

The complex genetic architecture of Alzheimer's disease: novel insights and future directions

Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease

Genetics impact risk of Alzheimer’s disease through mechanisms modulating structural brain morphology in late life

Genome-wide significant, replicated and functional risk variants for Alzheimer's disease.

Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology.

Associations of Alzheimer’s Disease Risk Variants with Gene Expression, Amyloidosis, Tauopathy, and Neurodegeneration

Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis

Association of Common and Rare Variants with Alzheimer's Disease in over 13,000 Diverse Individuals with Whole-Genome Sequencing from the Alzheimer's Disease Sequencing Project

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

Deep Post-Gwas Analysis Identifies Potential Risk Genes and Risk Variants for Alzheimer’s Disease, Providing New Insights into Its Disease Mechanisms

Genetic and multi-omic risk assessment of Alzheimer's disease implicates core associated biological domains

Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning

Association of CR1, CLU and PICALM with Alzheimer's Disease in a Cohort of Clinically Characterized and Neuropathologically Verified Individuals.

Identification of 16 novel Alzheimer's disease susceptibility loci using multi-ancestry meta-analyses of clinical Alzheimer's disease and AD-by-proxy cases from four whole genome sequencing datasets

Genetic, Clinical Underpinnings of Brain Change along Two Neuroanatomical Dimensions of Clinically-defined Alzheimer’s Disease

Genetic and clinical correlates of two neuroanatomical AI dimensions in the Alzheimer's disease continuum

Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis